Abstract 919P
Background
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) is a non-invasive imaging modality. This study aimed to investigate the effects of radiometric parameters and clinical characteristics of 18F-FDG PET-CT on the prognosis of patients with nasopharyngeal carcinoma (NPC).
Methods
A total of 801 patients with metastatic NPC were enrolled between 2016 and 2020, and all participants underwent 18F-FDG PET/CT before treatment. We assessed the following 18F-FDG PET parameters: standardized uptake value (SUV), SUV-avg (average), SUV-peak (maximum), and total lesion glycolysis (TLG) of the primary tumor and regional lymph nodes. We used multivariate Cox proportional hazards models and multiple machine learning techniques to identify independent predictors of survival based on radiomic parameters and patient clinical characteristics. After selecting the features, we established prognosis models using a COX stepwise regression model. Finally, we performed internal validation, and a nomogram was created for NPC comprehensive diagnosis.
Results
In this study, we developed a stable and robust model incorporating five independent prognostic features based on COX regression. The area under the curve (AUC) of the model was 0.75 (95% CI = 0.52–0.97) at 1 year, 0.80 (95% CI = 0.71–0.89) at 3 years, and 0.86 (95% CI = 0.78–0.94) at 5 years. The AUC at 3 years and 5 years were calculated as 0.7276 and 0.7242, respectively. The model was validated using receiver operating characteristic (ROC), consistency index, and multivariate analysis, which showed high accuracy and consistent performance. Moreover, patients in the low-risk score group exhibited significantly better outcomes than those in the high-risk score group (P < 0.001).
Conclusions
Our findings suggest that age, SUV-Tmax, SUV-Tavg, SUV-Tpeak, and TLG-T are valuable parameters for predicting long-term survival in patients with NPC. The nomogram based on metabolic parameters combined with other variables showed good prognostic accuracy in predicting NPC prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12